Endemic in over
over 100
Countries
#LetsTurnDengueAround

84 Countries

show evidence of Zika
AS OF MARCH 2017
#LetsTurnZikaAround
estimated
$60.3 BILLION
ANNUAL ECONOMIC
IMPACT WORLDWIDE
#LetsTurnNorovirusAround
37 REPORTED
cases in 2016
#LetsTurnPolioAround
Scroll Down

THE NUMBERS ARE CHANGING

THE NUMBERS ARE CHANGING

Take a closer look at worldwide infectious disease facts and statistics. Take a closer look at worldwide infectious
disease facts and statistics.
world map
  • Dengue
    Map shows areas at risk for dengue transmission.
  • Zika
    Map shows areas that have or have had Zika transmission.
  • Norovirus
    Map shows areas with the risk of norovirus transmission.
  • Polio
    Map shows areas where wild-type polio is endemic.
  • Dengue facts

    About 50% of the world's population lives under the threat of dengue, which is responsible for approximately 390 million infections globally per year.

  • Dengue facts

    Before 1970, only nine countries had experienced severe dengue epidemics. The disease is now endemic in more than 100 countries.

  • Zika facts

    As of March 2017, there were 84 countries and territories in the world with continuing mosquito-borne transmission of Zika.

  • Zika facts

    As of March 2017, a decline in cases of Zika infection has been reported in some countries, or in some parts of countries; WHO advises that vigilance needs to remain high.

  • Norovirus facts

    Norovirus is the most common viral cause of acute gastroenteritis worldwide, responsible for greater than 90% of epidemic non-bacterial outbreaks of gastroenteritis.

  • Norovirus facts

    Norovirus is estimated to cause more than 699 million illness cases each year.

  • Polio facts

    As of April 2017, polio remains endemic to only three countries (Afghanistan, Nigeria, and Pakistan), with 80% of the world now living in certified polio-free regions.

  • Polio facts

    Polio cases have decreased by over 99% since 1988, from an estimated 350,000 cases, to only 37 cases in 2016.

  • Interested in
    Learning More?

    For updated disease information and statistics, please visit the following websites:

    Back to disease facts and statistics

vaccines change numbers

If all children were

immunized

with existing

vaccines, by 2020

we would

save nearly

25,000,000

lives

If all children were immunized with

existing vaccines,

by 2020 we would

save nearly

25,000,000 lives

Estimated

2-3 MILLION

deaths averted each year with

immunization

from diphtheria, tetanus,

pertussis (whooping cough), and measles

Estimated 2-3 MILLION

deaths averted each year with

immunization

from diphtheria, tetanus, pertussis (whooping cough), and measles

vaccines change lives

infectious diseases
that need our attention

infectious diseases that
need our attention

Learn about some of the diseases we are focusing on. Learn about some of the diseases
we are focusing on.
slide image

DENGUE

About the disease

Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.

slide image

ZIKA

About the disease:

Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.

slide image

NOROVIRUS

About the disease:

Norovirus is the most common cause of viral gastroenteritis worldwide. It is spread directly through person-to-person contact, with the greatest burden on young children, older adults, and other vulnerable populations.

slide image

POLIO

About the disease:

Poliomyelitis (polio) is a highly infectious viral disease transmitted by person-to-person spread, mainly affecting young children. In some cases, polio can invade the nervous system and cause paralysis. Polio cases have decreased by more than 99% since 1988. The reduction is the result of the global effort to eradicate the disease.

slide image

DENGUE

About the disease

Dengue fever is the world’s fastest spreading mosquito-borne viral disease with about 50% of the world's population at risk for contracting the disease. Dengue fever affects children and adults alike with flu-like symptoms and potentially deadly complications.

slide image

ZIKA

About the disease:

Zika is a mosquito-borne virus that can be passed from a pregnant woman to her fetus. Though many infected people will not develop any symptoms at all, approximately 10% of congenital infections are associated with Zika virus-associated birth defects. WHO says that 31 countries have currently reported microcephaly and other central nervous system defects potentially associated with Zika virus.

slide image

NOROVIRUS

About the disease:

Norovirus is the most common cause of viral gastroenteritis worldwide. It is spread directly through person-to-person contact, with the greatest burden on young children, older adults, and other vulnerable populations.

slide image

POLIO

About the disease:

Poliomyelitis (polio) is a highly infectious viral disease transmitted by person-to-person spread, mainly affecting young children. In some cases, polio can invade the nervous system and cause paralysis. Polio cases have decreased by more than 99% since 1988. The reduction is the result of the global effort to eradicate the disease.

WHO WE ARE

WHO WE ARE

OUR VISION

OUR VISION

To protect the health of people everywhere through vaccines that address the most important infectious diseases.

OUR MISSION

OUR MISSION

To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.

OUR VALUES

OUR VALUES

In our day-to-day work, we focus on the following values while upholding the highest ethical standards:

  • .Fairness
  • .Honesty
  • .Integrity
  • .Perseverence

OUR PRODUCTS

OUR PRODUCTS

OUR PRODUCTS MARKETED IN JAPAN
  • .BLB-750 (H5N1 Flu)
  • .Measles Rubella
  • .Mumps
  • .Diphtheria Tetanus Toxoid
  • .Seasonal Flu
    (Denka & Kaketsuken)
  • .Varicella (Biken)
  • .Japanese Encephalitis (Biken)

OUR PRODUCTS MARKETED IN JAPAN

  • .Seasonal Flu
    (Denka & Kaketsuken)
  • .Varicella (Biken)
  • .Japanese Encephalitis
    (Biken)
  • .BLB-750 (H5N1 Flu)
  • .Measles Rubella
  • .Mumps
  • .Diphtheria Tetanus
    Toxoid

OUR VISION

To protect the health of people everywhere through vaccines that address the most important infectious diseases.

OUR MISSION

To develop and deliver innovative vaccines that tackle the toughest problems in public health and improve the lives of people around the world.

OUR VALUES

In our day-to-day work, we focus on the following values while upholding the highest ethical standards:

  • .Fairness
  • .Honesty
  • .Integrity
  • .Perseverence

OUR PRODUCTS

OUR PRODUCTS MARKETED IN JAPAN
  • .BLB-750 (H5N1 Flu)
  • .Measles Rubella
  • .Mumps
  • .Diphtheria Tetanus Toxoid
  • .Seasonal Flu
    (Denka & Kaketsuken)
  • .Varicella (Biken)
  • .Japanese Encephalitis (Biken)

OUR PRODUCTS MARKETED IN JAPAN

  • .Seasonal Flu
    (Denka & Kaketsuken)
  • .Varicella (Biken)
  • .Japanese Encephalitis
    (Biken)
  • .BLB-750 (H5N1 Flu)
  • .Measles Rubella
  • .Mumps
  • .Diphtheria Tetanus
    Toxoid

WE'RE COMMITTED
TO A HEALTHIER FUTURE

WE'RE COMMITTED
TO A HEALTHIER FUTURE

Here's what we are working on: Here's what we are working on:
Pipeline Summary

global pipeline summary

  • Phase 3

     

     

    DENGUE (TAK-003)

  • Phase 2

     

     

    NOROVIRUS (TAK-214)
    POLIO (TAK-195)

  • Phase 1

     

     

    ENTEROVIRUS (EV71) (TAK-021)
    ZIKA (TAK-426)

  • Preclinical

     

     

    CHIKUNGUNYA (TAK-507)

slide image

DENGUE

Takeda's vaccine candidate:

A live attenuated tetravalent dengue vaccine is being developed.

Development Phase: Phase 3

slide image

NOROVIRUS

Takeda's vaccine candidate:

A virus-like particle vaccine for two norovirus strains is being developed.

Development Phase: Phase 2b

slide image

POLIO

Takeda's vaccine candidate:

A Sabin-strain inactivated polio vaccine (sIPV) is being developed with support from the Bill and Melinda Gates Foundation.

Development Phase: Phase 2

slide image

ENTEROVIRUS 71 (EV17)

Takeda's vaccine candidate:

An inactivated virus vaccine for EV71 is being developed.

Development Phase: Phase 1

slide image

ZIKA

Takeda's vaccine candidate:

An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Development Phase: Phase 1

slide image

CHIKUNGUNYA

Takeda's vaccine candidate:

A chikungunya vaccine is being developed in partnership with Zydus Cadila.

Development Phase: Preclinical

slide image

GLOBAL PIPELINE SUMMARY

  • Phase 3
    DENGUE (TAK-003)
  • Phase 2
    NOROVIRUS (TAK-214)
    POLIO (TAK-195)
  • Phase 1
    ENTEROVIRUS 71 (EV71) (TAK-021)
    ZIKA (TAK-426)
  • Preclinical
    CHIKUNGUNYA (TAK-507)
slide image

DENGUE

Takeda's vaccine candidate:

A live attenuated tetravalent dengue vaccine is being developed.

Development Phase: Phase 3

slide image

NOROVIRUS

Takeda's vaccine candidate:

A virus-like particle vaccine for two norovirus strains is being developed.

Development Phase: Phase 2b

slide image

POLIO

Takeda's vaccine candidate:

A Sabin-strain inactivated polio vaccine (sIPV) is being developed with support from the Bill and Melinda Gates Foundation.

Development Phase: Phase 2

slide image

ENTEROVIRUS 71 (EV17)

Takeda's vaccine candidate:

An inactivated virus vaccine for EV71 is being developed.

Development Phase: Phase 1

slide image

ZIKA

Takeda's vaccine candidate:

An inactivated, adjuvanted, whole Zika virus vaccine is being developed with support from the U.S. Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA).

Development Phase: Phase 1

slide image

CHIKUNGUNYA

Takeda's vaccine candidate:

A chikungunya vaccine is being developed in partnership with Zydus Cadila.

Development Phase: Preclinical

NEWSROOM: WE'RE MAKING PROGRESS

NEWSROOM:
WE'RE MAKING PROGRESS

Takeda is taking steps towards making an impact on public
health by developing innovative new vaccines.
Takeda is taking steps towards making an
impact on public health by developing
innovative new vaccines.

Swipe to see the five most recent press releases from the Takeda Vaccine Business.

Click the arrows to see the five most recent press releases from the Takeda Vaccine Business.

January 29, 2018

Takeda’s Zika Vaccine Candidate Receives U.S. FDA Fast Track Designation

November 28, 2017

Takeda Initiates Phase 1 Clinical Trial of Zika Vaccine Candidate

November 07, 2017

Takeda’s Dengue Vaccine Candidate Associated with Reduced Incidence of Dengue in Children and Adolescents; New 18-Month Interim Phase 2 Data Published in The Lancet Infectious Diseases

June 26, 2017

Takeda and Biological E. Limited Announce Partnership to Develop Low-Cost Combination Vaccines for Low- and Middle-Income Countries around the Globe

May 09, 2017

Takeda Terminates Plans for VAXEM Hib® Launch in Japan Due to the Vaccine Supplier’s (GSK) Decision to Discontinue Global Production

leading the way

leading the way

Meet the people who are committed to making change. Meet the people who are committed
to making change.
Takeda Vaccine Business Leadership
Takeda Vaccine Business Leadership
Our team is working passionately toward improving public health.
Click to meet our leaders Swipe to meet our leaders

RAJEEV VENKAYYA, MD

President, Takeda Vaccine Business

Rajeev is President of the Takeda Vaccine Business. He joined Takeda in 2012 to launch the global vaccine business. He was previously Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation, and prior to that, Special Assistant to the President for Biodefense at the White House.

JOHN BOSLEGO, MD

Head of Development

John is Head of Development for the Takeda Vaccine Business. His prior experience includes Director of the Vaccine Development Global Program at PATH, Executive Director at Merck Research Laboratories and the Deputy Director at the Walter Reed Army Institute of Research in Washington, DC.

Rahul Singhvi, ScD, MBA

Chief Operating Officer and Head of Vaccine Operations

Rahul is Chief Operating Officer, leads the Vaccine Operations team, and is responsible for the global supply of vaccines at Takeda. He has a wealth of experience in vaccine development and manufacturing. Before joining Takeda, Rahul was President and CEO of Novavax.

TAKAYUKI NAKANO, PhD, MBA

Head of Business Planning, Japan Business Coordinator

Takayuki is Head of Business Planning and Japan Business Coordinator. As Head of Business Planning, Takayuki is responsible for business strategy planning, vaccine portfolio management and ensuring organizational governance. As Japan Business Coordinator, he works on strengthening coordination between Japan-based functions and their global counterparts. Takayuki joined Takeda in 2000 and worked in Takeda’s R&D organization prior to joining the Vaccine business.

Gary Dubin, MD

Head of Global Medical Office

Gary is the Senior Vice President, Head of the Global Medical Office, and leads the Takeda Vaccine Business Medical Affairs and Policy team. He is responsible for vaccines safety and medical governance. He spent the previous 20 years at GSK Vaccines.

Hansi Dean, PhD

Head of Discovery Research

Hansi is Head of Discovery Research for the Takeda Vaccine Business. Hansi joined Takeda in 2014. She was previously Director of New Alliances at the International AIDS Vaccine Initiative, and prior to that a Director at PowderJect and Group Leader for Viral Vaccine Development at Schering Plough.

Elena Cant, BS, MBA

Head of Commercial

Elena is the Takeda Vaccine Business' Head of Global Commercial, and was previously Head of Global Business Operations for the Takeda Vaccine Business, which she joined in 2012. Prior to joining Takeda, Elena worked at McKinsey & Company, Hospira, and at Mead Johnson Nutrition.

Tetsu Inada, BS, MBA

Head of Finance

Tetsu has been Head of Finance for the Takeda Vaccine Business since 2013. Prior to that Tetsu was at Millennium Pharmaceuticals since 2001, and he joined Takeda through the acquisition of Millennium in 2008.

Lisa Amaya, MA, MBA

Head of Human Resources

Lisa is Head of Human Resources for the Takeda Vaccine Business. Lisa joined Takeda in 2016 from Biogen, where she was Senior Director of HR for R&D. Prior to Biogen, Lisa held senior HR roles at the Interpublic Group, Metro International and American Financial Systems Inc.

Our team is working passionately toward improving public health.

RAJEEV VENKAYYA, MD

President, Takeda Vaccine Business

Rajeev is President of the Takeda Vaccine Business. He joined Takeda in 2012 to launch the global vaccine business. He was previously Director of Vaccine Delivery in the Global Health Program at the Bill & Melinda Gates Foundation, and prior to that, Special Assistant to the President for Biodefense at the White House.

JOHN BOSLEGO, MD

Head of Development

John is Head of Development for the Takeda Vaccine Business. His prior experience includes Director of the Vaccine Development Global Program at PATH, Executive Director at Merck Research Laboratories and the Deputy Director at the Walter Reed Army Institute of Research in Washington, DC.

Rahul Singhvi, ScD, MBA

Chief Operating Officer and Head of Vaccine Operations

Rahul is Chief Operating Officer, leads the Vaccine Operations team, and is responsible for the global supply of vaccines at Takeda. He has a wealth of experience in vaccine development and manufacturing. Before joining Takeda, Rahul was President and CEO of Novavax.

TAKAYUKI NAKANO, PhD, MBA

Head of Business Planning, Japan Business Coordinator

Takayuki is Head of Business Planning and Japan Business Coordinator. As Head of Business Planning, Takayuki is responsible for business strategy planning, vaccine portfolio management and ensuring organizational governance. As Japan Business Coordinator, he works on strengthening coordination between Japan-based functions and their global counterparts. Takayuki joined Takeda in 2000 and worked in Takeda’s R&D organization prior to joining the Vaccine business.

Gary Dubin, MD

Head of Global Medical Office

Gary is the Senior Vice President, Head of the Global Medical Office, and leads the Takeda Vaccine Business Medical Affairs and Policy team. He is responsible for vaccines safety and medical governance. He spent the previous 20 years at GSK Vaccines.

Hansi Dean, PhD

Head of Discovery Research

Hansi is Head of Discovery Research for the Takeda Vaccine Business. Hansi joined Takeda in 2014. She was previously Director of New Alliances at the International AIDS Vaccine Initiative, and prior to that a Director at PowderJect and Group Leader for Viral Vaccine Development at Schering Plough.

Elena Cant, BS, MBA

Head of Commercial

Elena is the Takeda Vaccine Business' Head of Global Commercial, and was previously Head of Global Business Operations for the Takeda Vaccine Business, which she joined in 2012. Prior to joining Takeda, Elena worked at McKinsey & Company, Hospira, and at Mead Johnson Nutrition.

Tetsu Inada, BS, MBA

Head of Finance

Tetsu has been Head of Finance for the Takeda Vaccine Business since 2013. Prior to that Tetsu was at Millennium Pharmaceuticals since 2001, and he joined Takeda through the acquisition of Millennium in 2008.

Lisa Amaya, MA, MBA

Head of Human Resources

Lisa is Head of Human Resources for the Takeda Vaccine Business. Lisa joined Takeda in 2016 from Biogen, where she was Senior Director of HR for R&D. Prior to Biogen, Lisa held senior HR roles at the Interpublic Group, Metro International and American Financial Systems Inc.

1World

It's the single thing that
that connects us all